Akèy › Kansè san › Texas › Houston
Etid klinik pou Kansè san nan Houston, TX
46 etid pou Kansè san ap chèche patisipan nan sit nan ak bò kote Houston (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Ap rekriteFaz 3
- University of Texas MD Anderson Cancer Center ( Site 0007), Houston
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- UT MD Anderson Cancer Center, Houston
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Ap rekriteEtid obsèvasyon
- Texas Children's Hospital, Houston
A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies
Ap rekriteFaz 1
- MD Anderson Cancer Center - University of Texas, Houston
Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia
Ap rekriteFaz 3
- Quetzal Site 6, Houston
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
Ap rekriteFaz 1
- UT MD Anderson Cancer Center, Houston
Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease
Ap rekriteFaz 1 bonè
- M D Anderson Cancer Center, Houston
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Ap rekriteFaz 3
- The University of Texas MD Anderson Cancer Center, Houston
Bone Marrow Imaging and Clinical Outcomes Across Hematologic, Oncologic, and Other Relevant Conditions
Ap rekriteEtid obsèvasyon
- UT MD Anderson Cancer Center, Houston
Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)
Ap rekriteFaz 1
- Texas Children's Hospital, Houston
- The Methodist Hospital, Houston
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
Ap rekriteFaz 2
- The University of Texas MD Anderson Cancer Center, Houston
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Ap rekriteFaz 1
- Md Anderson Cancer Center, Houston
Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure
Ap rekrite
- M D Anderson Cancer Center, Houston
Impact of Project ECHO on Improving the Quality of Palliative Care in Patients With Advanced Cancer and Their Caregivers in Underserved Areas of Kenya, Nigeria, Ghana, South Africa, India, and Ethiopia
Ap rekriteFaz 2Volontè an sante akeyi
- M D Anderson Cancer Center, Houston
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Ap rekriteFaz 1
- M D Anderson Cancer Center, Houston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Ap rekriteFaz 1/2
- MD Anderson, Houston
Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Ap rekriteFaz 3
- University of Texas, Houston
Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances
Ap rekriteFaz 1/2
- M D Anderson Cancer Center, Houston
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion
Ap rekriteFaz 1 bonè
- M D Anderson Cancer Center, Houston
Expressive Writing for the Management of Stress in Cancer Survivors
Ap rekrite
- M D Anderson Cancer Center, Houston
The Impact of COVID-19 on Pulmonary Procedures
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- M D Anderson Cancer Center, Houston
Complications and Clinical Response in Cancer Patients Treated With Anti-VEGF-Related Therapies
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
PUL-042 Treatment in Patients With Parainfluenza Virus (PIV), Human Metapneumovirus (hMPV) or Respiratory Syncytial Virus (RSV)
Ap rekriteFaz 2
- University of Texas MD Anderson MD Anderson Cancer Center, Houston
A Study of APG-3288 in Relapsed/Refractory Blood Cancers
Ap rekriteFaz 1
- The University of TX MD Anderson Cancer Center, Houston
Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Ap rekriteEtid obsèvasyon
- M.D. Anderson Cancer Center, Houston
- Texas Children's Hospital - Baylor Medical Center, Houston
Improving Comprehensive Care of Cancer Patients
Ap rekriteVolontè an sante akeyi
- Baylor College of Medicine, Houston
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
The Effect of COVID-19 Pandemic on Adolescent and Young Adult Cancer Patients and Survivors
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
Formulating Expert Consensus Guidelines in Cancer Care Using the Delphi Method
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- M D Anderson Cancer Center, Houston
Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
Ap rekriteFaz 2
- M D Anderson Cancer Center, Houston
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Ap rekriteFaz 3
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
Ap rekrite
- M D Anderson Cancer Center, Houston
Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation
Ap rekriteFaz 2
- The University of Texas M. D. Anderson Cancer Center, Houston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Ap rekriteFaz 1/2
- The University of Texas MD Anderson Cancer Center, Houston
Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies
Ap rekriteEtid obsèvasyon
- M D Anderson Cancer Center, Houston
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
Ap rekriteFaz 1/2
- University of Texas MD Anderson Cancer Center, Houston
Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Ap rekriteFaz 1
- Texas Children's Hospital/Baylor College of Medicine, Houston
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Ap rekriteFaz 1
- MD Anderson Cancer Center, Houston
Etid Kansè san nan lòt vil
- New York City, NY26 etid
- Boston, MA25 etid
- Washington, DC19 etid
- Baltimore, MD18 etid
- Seattle, WA18 etid
- Los Angeles, CA17 etid
- Durham, NC16 etid
- Chicago, IL15 etid
- Philadelphia, PA14 etid
- Nashville, TN13 etid
- Atlanta, GA13 etid
- Edison, NJ13 etid
Lòt etid nan Houston
- Kansè Poumon ki pa ti selil145 etid
- Kansè nan tete126 etid
- Kansè (tout kalite)121 etid
- Kansè Metastatik104 etid
- Kansè kolorektal102 etid
- Kansè ovè89 etid
- Leksemi mieloïd egi85 etid
- Kansè poumon78 etid
- Kansè pwostat76 etid
- Kansè Endomèt68 etid
- Kansè pankreyas61 etid
- Melanom59 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.